Pharmaceutical Research & Manufacturers of America v. County of Alameda

768 F.3d 1037, 2014 U.S. App. LEXIS 18737, 2014 WL 4814407
CourtCourt of Appeals for the Ninth Circuit
DecidedSeptember 30, 2014
Docket13-16833
StatusPublished
Cited by8 cases

This text of 768 F.3d 1037 (Pharmaceutical Research & Manufacturers of America v. County of Alameda) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pharmaceutical Research & Manufacturers of America v. County of Alameda, 768 F.3d 1037, 2014 U.S. App. LEXIS 18737, 2014 WL 4814407 (9th Cir. 2014).

Opinion

OPINION

N.R. SMITH, Circuit Judge:

The Supreme Court “has adopted what amounts to a two-tiered approach to analyzing state economic regulation under the *1040 Commerce Clause.” Broum-Forman Distillers Corp. v. N.Y. State Liquor Auth., 476 U.S. 573, 578-79, 106 S.Ct. 2080, 90 L.Ed.2d 552 (1986).

When a state statute directly regulates or discriminates against interstate commerce, or when its effect is to favor in-state economic interests over out-of-state interests, [the Court has] generally struck down the statute without further inquiry.
When, however, a statute has only indirect effects on interstate commerce and regulates evenhandedly, [the Court has] examined whether the State’s interest is legitimate and whether the burden on interstate commerce clearly exceeds the local benefits.

Id. at 579, 106 S.Ct. 2080 (citations omitted). Because the Alameda County Safe Drug Disposal Ordinance (the “Ordinance”) passes constitutional muster under this two-tiered approach, we affirm the district court.

FACTS

The facts are not in dispute. Alameda County (“Alameda”) passed the Ordinance in July of 2012. The Ordinance requires that prescription drug manufacturers, who either sell, offer for sale, or distribute “Covered Drugs” in Alameda, operate and finance a “Product Stewardship Program.” The term “Covered Drug” includes “all drugs in 21 U.S.C. § 321(g)(1) of the Federal Food, Drug and Cosmetic Act ... including both brand name and Generic Drugs.” To operate and finance a Product Stewardship Program, the manufacturers must provide for the collection, transportation, and disposal of any unwanted Covered Drug — no matter which manufacturer made the drug in question.

Facially, the Ordinance applies equally to both manufacturers located within Alameda and manufacturers located outside the county. While some manufacturers have their corporate offices or principal places of business in Alameda, all prescription drugs currently sold arrive in Alameda via inter-county or interstate commerce; even drugs manufactured in Alameda are shipped to other counties for packaging and then shipped back into Alameda. Alameda estimates that its total 2010 prescription drug retail sales were approximately $965 million and neither party asserts that sales have declined since then.

Pursuant to the Ordinance, manufacturers must set up disposal kiosk sites throughout Alameda. The kiosks will consist of disposal bins located in areas “convenient and adequate to serve the [disposal] needs of Alameda County residents.” Manufacturers must also promote the stewardship program to the public via “educational and outreach materials.” After collection, the prescription drugs must be destroyed at medical waste facilities.

The manufacturers are free to individually operate separate product stewardship programs or to jointly operate a program with one or more other manufacturers. If manufacturers choose to operate a program jointly, the Ordinance requires that the program’s costs be spread fairly and reasonably among the manufacturers. The manufacturers may run the stewardship program themselves, or they may pay a third-party to operate the stewardship program on their behalf. Assuming the manufacturers jointly operated a stewardship program, the start-up costs would approximate $1,100,000. Around $200,000 of the start-up costs consists of reimbursement to Alameda for the county’s costs to administer the Ordinance. While Plaintiffs estimate the subsequent annual costs to maintain the stewardship program to be around $1,200,000, Alameda estimates annual maintenance costs of only $330,000. *1041 However, both parties agreed this difference in estimates was immaterial for summary judgment purposes. Alameda estimates an annual cost of $200,000 per year to oversee the stewardship program and the Ordinance requires the manufacturers to reimburse Alameda for this cost. Using these numbers, Alameda estimates a total annual cost to each manufacturer between $5,300 and $12,000. Under the Ordinance, manufacturers may not implement a point-of-sale “tax” or fee to recoup the stewardship program’s administrative costs.

Plaintiffs, non-profit trade organizations representing the manufacturers and distributors of pharmaceutical products, claim that the Ordinance violates the dormant Commerce Clause by requiring interstate drug manufacturers to conduct and pay for Alameda County’s drug disposal program. The district court disagreed and granted Defendants’ motion for summary judgment.

STANDARD OF REVIEW

“We review de novo the district court’s grant of summary judgment.” Smith v. Clark Cnty. Sch. Dist., 727 F.3d 950, 954 (9th Cir.2013).

DISCUSSION

The Commerce Clause dictates that “Congress shall have Power ... [t]o regulate Commerce ... among the several States.” U.S. Const, art. I, § 8, cl 3. “Though phrased as a grant of regulatory power to Congress, the Clause has long been understood to have a ‘negative’ aspect that denies the States the power unjustifiably to discriminate against or burden the interstate flow of articles of commerce.” Or. Waste Sys., Inc. v. Dep’t of Envtl. Quality of State of Or., 511 U.S. 93, 98, 114 S.Ct. 1345, 128 L.Ed.2d 13 (1994). “The modern law of what has come to be called the dormant Commerce Clause is driven by concern about economic protectionism that is, regulatory measures designed to benefit instate economic interests by burdening out-of-state competitors.” Dep’t of Revenue of Ky. v. Davis, 553 U.S. 328, 337-38, 128 S.Ct. 1801, 170 L.Ed.2d 685 (2008) (internal quotation marks omitted). We analyze dormant Commerce Clause claims using the Supreme Court’s two-tiered approach. See Brown-Forman, 476 U.S. at 578-79, 106 S.Ct. 2080.

I.

The first tier asks whether the Ordinance “either discriminates against or directly regulates interstate commerce.” Greater L.A Agency on Deafness, Inc. v. Cable News Network, Inc., 742 F.3d 414, 432 (9th Cir.2014). If the Ordinance does either of these things, “it violates the Commerce Clause per se, and we must strike it down without further inquiry.” NCAA v. Miller, 10 F.3d 633, 638 (9th Cir.1993). The Ordinance does neither.

A. Discrimination

A statute is discriminatory if it “impose[s] commercial barriers or discriminates against an article of commerce by reason of its origin or destination out of State.” C & A Carbone, Inc. v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Elizabeth Flynt v. Rob Bonta
131 F.4th 918 (Ninth Circuit, 2025)
Direct Energy Services, LLC v. Public Utilities Regulatory Authority
347 Conn. 101 (Supreme Court of Connecticut, 2023)
Arlene Rosenblatt v. City of Santa Monica
940 F.3d 439 (Ninth Circuit, 2019)
Safari Club International v. Becerra
702 F. App'x 607 (Ninth Circuit, 2017)
Publius v. Boyer-Vine
237 F. Supp. 3d 997 (E.D. California, 2017)
Puppies 'N Love v. City of Phoenix
116 F. Supp. 3d 971 (D. Arizona, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
768 F.3d 1037, 2014 U.S. App. LEXIS 18737, 2014 WL 4814407, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pharmaceutical-research-manufacturers-of-america-v-county-of-alameda-ca9-2014.